ExoCoBio Inc. raises $26.7M in Series B Funding

๊ด€๋ฆฌ์ž
11 Jan 2019
Views 10249

5c37f7465247b.jpg


ย ExoCoBio Inc. announced that it recently raised about $27 million in its series B funding. Top tier Korean investors participated in this round, including Seven Tree Equity Partners, CSQUARED Global Asset Management, TS Investment Partners, K2 Investment, Intervest, KDB Capital, Atinum Investment, GU Equity Partners, QUANTUM Ventures Korea, Platinum technology Investment.

Since it was established in January 2017, ExoCoBio has raised about $46 million accumulatively including series A round in April 2017 of $11 million.

Series B money will be used to set up GMP-compliant exosome manufacturing facilities to produce exosome pharmaceuticals, to attract thigh quality talents, and to secure additional business opportunities for commercialization in cosmetics industry.

โ€œWe are very delighted by the level of enthusiasm and financial support from our investorsโ€ said Byong Cho, CEO of ExoCoBio. โ€œAnd we are going to step up our R&D and business so that ExoCoBio will be one of leaders in the global exosome industry.โ€

Recently, ExoCoBio published a scientific paper on that stem cell-derived exosomes dramatically can improve atopic dermatitis and inhibit a variety of inflammatory targets in the journal of Stem Cell Research and Therapy, which is the worldโ€™s first

In cosmeceutical business, ExoCoBio has been launching its own exosome-based brands and products, such as EXOMAGETM, CelltweetTM and ASCE+TM.
<!--[if !supportLineBreakNewLine]-->

0 170